We develop novel and differentiated oral small molecule therapies for patients suffering from diseases with significant unmet medical need
We are a clinical stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly owned research and development facility, and a team with significant expertise and experience in the development of compounds that targets nuclear receptors, transcription factors and epigenetic modulation.
By leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
Therapeutic Areas
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.
Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of NASH: inflammation, steatosis, ballooning, and importantly fibrosis.
Lanifibranor completed a phase IIb study. After only 6 months of treatment, lanifibranor achieved statistically significance in both regulatory endpoints required by FDA and EMA, resolution of NASH without worsening of fibrosis and reduction in fibrosis without worsening of NASH. These results, in addition to an excellent safety profile, clearly difference lanifibranor from any other treatment in development for NASH. For more details of the headline results see the results presentation.
Mucopolysaccharidosis (MPS)
MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
In the recently completed iMProveS phase IIa study odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.
